{"id": "patient_01_q0", "generated_text": "D: Vincristine\nThe context provided does not mention Vincristine in Mrs. Sample's current treatment regimen for her DLBCL. The current treatment regimen for Mrs. Sample includes Polatuzumab vedotin, Rit", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q0", "generated_text": "D: Vincristine\nThe context provided does not mention Vincristine as part of Mrs. Sample's treatment regimen. The current treatment regimen mentioned for Mrs. Sample includes Polatuzumab vedotin, Rituximab", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q0", "generated_text": "D: Vincristine\n: The context provided does not mention Vincristine (vincristine) as part of the current treatment regimen for Mrs. Sample's DLBCL. The treatment regimen described includes Polatuzumab ved", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q1", "generated_text": "D: She has 3-vessel CHD. is NOT accurate based on the provided information. The context mentions that Mrs. Sample has a \"2-vessel CHD\" (two-vessel coronary heart disease). Options A, B, C", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q1", "generated_text": "D: She has 3-vessel CHD. is NOT accurate based on the provided information. The context states that Mrs. Sample has a 2-vessel CHD, not a 3-vessel CHD. The other options (2", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q1", "generated_text": "D: She has 3-vessel CHD. is NOT accurate based on the provided information. The context states she has 2-vessel CHD. A: She has 2-vessel disease: B: She was diagnosed with primary progressive", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q2", "generated_text": "A: Mrs. Sample suffers from Primary progressive type of multiple sclerosis as indicated in the medical history. Other diagnoses include mood disorder, 2-vessel CHD, and chronic inflammatory disease of the CNS suggestive of multiple sclerosis. The MRI findings, especially", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q2", "generated_text": "A: Mrs. Sample suffers from primary progressive type of multiple sclerosis, which is noted in her medical history and other diagnoses. : The context clearly mentions that Mrs. Sample was diagnosed with primary progressive type of multiple sclerosis (ID 03/0", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q2", "generated_text": "A: Mrs. Sample suffers from primary progressive type of multiple sclerosis. This is evident from the context, which mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" and \"Mood disorder.\" Although the context does not", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q3", "generated_text": "B: The patient takes Fingolimod (0.5 mg) as a 1 capsule at bedtime, Note: Take a break as directed.  Based on the information provided in the medical report, Mrs. Sample takes Fingol", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q3", "generated_text": "B: The patient takes Fingolimod (0.5 mg) in one capsule at bedtime, as directed.  The patient is instructed to take a break as directed.  : The patient takes Fingolimod (0.", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q3", "generated_text": "B: Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\nThe text explicitly states \"Fingolimod 0.5mg, 1 capsule at bedtime, Note", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q4", "generated_text": "D: Oncology board decided for 6 cycles of R-Pola-CHP. To continue the treatment, a break in Fingolimod use is recommended for re-evaluation in 4-5 months. The therapy is to be", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q4", "generated_text": "D: The oncology board recommended a regimen of 6 cycles of R-Pola-CHP for Mrs. Sample. This recommendation was made after a careful assessment of her response to the initial therapy and the need to continue monitoring her symptoms and side", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q4", "generated_text": "D: Oncology board decided on 6 cycles of R-Pola-CHP. To be continued as of 02/28/2017. To include bi-weekly lab tests (electrolytes, blood count", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q5", "generated_text": "C: The metastasis was located in the T10 vertebra, specifically in the thoracic vertebra area, as noted in the MRI and CT scans which indicate a metastatic lesion originating from the left pedicle of T10 with a", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q5", "generated_text": "C: The metastasis was located at the T10 level, specifically noted as a metastatic lesion originating from the left pedicle of T10 with a significant extramedullary tumor mass and full spinal canal narrowing at the level of T", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q5", "generated_text": "C: The metastasis was located at T10 in the thoracic vertebra, as mentioned in the pathology report stating \"Tumor cuff T10\" in the clinical information. This was surgically addressed. The other options like T8", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q6", "generated_text": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement. To determine the correct answer", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q6", "generated_text": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement. To answer the query,", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q6", "generated_text": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement. The context clearly indicates that", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q7", "generated_text": "B: Mrs. Sample received multiple radiologic examinations in the following order: MR Head (for incidental findings), MR Spine plain + post-contrast from 12/20/2016, CT Thoracic Spine from", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q7", "generated_text": "B: The patient received multiple radiologic examinations in the following order: MR Head (12/19/2016), MR Spine plain + post-contrast (12/20/2016), CT Thor", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q7", "generated_text": "B: Mrs. Sample received multiple radiologic examinations in the following order: MR Head (including MR Spine), MR thoracic/lumbar spine, CT chest/abdomen/pelvis, CT Thoracic Spine, CT Thoracic", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q8", "generated_text": "E: The patient started taking 2mg of Melatonin in the evening.\n\nThe context does not mention any change in the dose of Sertraline. The Aspirin was continued as per the context. There is no mention of Preg", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q8", "generated_text": "E: The patient started taking Melatonin 2mg (sustained-release), 1 tablet at bedtime. The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg. The patient started", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q8", "generated_text": "B: The patient started taking Pregabalin 75mg, 1-0-0-0. The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg. Aspir", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
{"id": "patient_01_q9", "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The context indicates a progression in the patient's pain management. Specifically, at admission, she was taking Hydromorphone hydro", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q9", "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The context provided shows an increase in the frequency of Hydromorphone (Dilaudid® or Exalgo® for", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 1}}
{"id": "patient_01_q9", "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The context indicates that the patient was initially prescribed Hydromorphone hydrochloride (extended-release) 2mg: Take", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 2}}
